Anti-CD100 neutralizing neutralizing antibodies and methods of using the same
AssigneeVaccinex, Inc.
InventorsErnest S. Smith, Terrence Lee Fisher
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.
Claims19
An isolated antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) polypeptide comprising VH-CDR1, VH-CDR2, and VH-CDR3 amino acid sequences comprising SEQ ID NOs:
- 6, 7, and 8, respectively, and a light chain variable region (VL) polypeptide comprising VL-CDR1, VL-CDR2, and VL-CDR3 amino acid sequences comprising SEQ ID NOs:
- 14, 15, and 16, respectively;
- wherein said antibody or antigen-binding fragment thereof specifically binds CD100.
An antibody or antigen-binding fragment thereof which specifically binds CD100, produced by a method comprising culturing a host cell comprising an isolated VH encoding polynucleotide and an isolated VL encoding polynucleotide, wherein said VH encoding polynucleotide encodes a VH polypeptide comprising VH-CDR1, VH-CDR2, and VH-CDR3 amino acid sequences consisting of SEQ ID NOs:
- 6, 7, and 8, respectively;
- wherein said VL encoding polynucleotide encodes a VL polypeptide comprising VL-CDR1, VL-CDR2, and VL-CDR3 amino acid sequences consisting of SEQ ID NOs:
- 14, 15, and 16, respectively;
- and wherein an antibody or antigen-binding fragment thereof encoded by said VH and VL encoding polynucleotides specifically binds CD100, and recovering said antibody or antigen-binding fragment thereof.
Dependencies are inferred from the claim text.